INDICATION FOR LIVER TRANSPLANTATION DUE TO HEPATOCELLULAR CARCINOMA: ANALYSIS OF 1,706 PROCEDURES OVER THE PAST DECADE IN THE STATE OF PARANÁ

Overview

Journal Arq Bras Cir Dig

Specialties Gastroenterology
General Surgery

Date 2022 Dec 21

PMID 36542003

Authors

Alexandre Coutinho Teixeira de Freitas

Fatima Diana Samudio Espinoza

Cristina Alvarez Mattar

Julio Cezar Uili Coelho

Affiliations

Soon will be listed here.

Abstract

Background: Patients listed for liver transplantation and hepatocellular carcinoma are considered priority on the waiting list, and this could overly favor them.

Aim: This study aimed to evaluate the impact of this prioritization.

Methods: We analyzed the liver transplants performed in adults from 2011 to 2020 and divided into three groups: adjusted Model of End-Stage Liver Disease (MELD) score for hepatocellular carcinoma, other adjusted Model of End-Stage Liver Disease situations, and no adjusted Model of End-Stage Liver Disease.

Results: A total of 1,706 patients were included in the study, of which 70.2% were male. Alcoholism was the main etiology of cirrhosis (29.6%). Of the total, 305 patients were with hepatocellular carcinoma, 86 with other adjusted Model of End-Stage Liver Disease situations, and 1,315 with no adjusted Model of End-Stage Liver Disease. Patients with hepatocellular carcinoma were older (58.9 vs. 53.5 years). The predominant etiology of cirrhosis was viral hepatitis (60%). The findings showed that group with adjusted Model of End-Stage Liver Disease had lower physiological Model of End-Stage Liver Disease (10.9), higher adjusted Model of End-Stage Liver Disease (22.6), and longer waiting list time (131 vs. 110 days), as compared to the group with no adjusted Model of End-Stage Liver Disease. The total number of transplants and the proportion of patients transplanted for hepatocellular carcinoma increased from 2011 to 2020. There was a reduction in the proportion of patients with hepatocellular carcinoma and adjusted Model of End-Stage Liver Disease of 20 and there was an increase on waiting list time in this group. There was an increase in the proportion of those with adjusted Model of End-Stage Liver Disease of 24 and 29, but the waiting list time remained stable.

Conclusion: Over the past decade, prioritization of hepatocellular carcinoma resulted in an increased proportion of transplanted patients in relation to those with no priority. It also increased waiting list time, requiring higher adjusted Model of End-Stage Liver Disease to transplant an organ.

Citing Articles

ADULT-TO-PEDIATRIC LIVING DONOR LIVER TRANSPLANT IN RECIPIENTS >20 KG: A CASE SERIES OF FULL LEFT LOBE GRAFTS.

Ortiz C, Meira Junior J, Pattillo J, Vinuela E, Jarufe N, Martinez J Arq Bras Cir Dig. 2024; 37:e1828.

PMID: 39475883 PMC: 11520676. DOI: 10.1590/0102-6720202400035e1828.

PROGNOSTIC FACTORS OF LIVER TRANSPLANTATION FOR ACUTE-ON-CHRONIC LIVER FAILURE.

Cronst J, Prediger L, Pinto M, Ferraz J, Mattos A, Alvares-da-Silva M Arq Bras Cir Dig. 2023; 36:e1779.

PMID: 38088725 PMC: 10712924. DOI: 10.1590/0102-672020230061e1779.

LIVER TRANSPLANTATION IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A MULTICENTRIC STUDY.

Wiederkehr H, Wiederkehr J, da Igreja M, Ramos E, Nogara M, Soffiatti D Arq Bras Cir Dig. 2023; 36:e1769.

PMID: 37851755 PMC: 10578153. DOI: 10.1590/0102-672020230051e1769.

THE OPTIMUM LEVEL OF MELD TO MINIMIZE THE MORTALITY ON LIVER TRANSPLANTATION WAITING LIST, AND LIVER TRANSPLANTED PATIENT IN SÃO PAULO STATE, BRAZIL.

Chaib E, Pessoa J, Struchiner C, Carneiro DAlbuquerque L, Massad E Arq Bras Cir Dig. 2023; 36:e1746.

PMID: 37729279 PMC: 10510095. DOI: 10.1590/0102-672020230028e1746.

HEPATOSPLENIC SCHISTOSOMIASIS-ASSOCIATED CHRONIC PORTAL VEIN THROMBOSIS: RISK FACTOR FOR HEPATOCELLULAR CARCINOMA?.

Darce G, Makdissi F, Ando S, Fonseca G, Pirola Kruger J, Coelho F Arq Bras Cir Dig. 2023; 36:e1763.

PMID: 37729278 PMC: 10510374. DOI: 10.1590/0102-672020230045e1763.

References

Llovet J, Fuster J, Bruix J . Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30(6):1434-40. DOI: 10.1002/hep.510300629. View

Pinto L, Coelho G, Coutinho M, Torres O, Leal P, Vieira C . RISK FACTORS ASSOCIATED WITH HEPATIC ARTERY THROMBOSIS: ANALYSIS OF 1050 LIVER TRANSPLANTS. Arq Bras Cir Dig. 2021; 33(4):e1556. PMC: 7836077. DOI: 10.1590/0102-672020200004e1556. View

Tan E, Goh B, Lee S, Krishnamoorthy T, Tan C, Jeyaraj P . Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center. Transplant Proc. 2018; 50(10):3564-3570. DOI: 10.1016/j.transproceed.2018.08.032. View

Meirelles Junior R, Salvalaggio P, de Rezende M, Evangelista A, Della Guardia B, Matielo C . Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo). 2015; 13(1):149-52. PMC: 4977591. DOI: 10.1590/S1679-45082015RW3164. View

Santopaolo F, Lenci I, Milana M, Manzia T, Baiocchi L . Liver transplantation for hepatocellular carcinoma: Where do we stand?. World J Gastroenterol. 2019; 25(21):2591-2602. PMC: 6558441. DOI: 10.3748/wjg.v25.i21.2591. View

Freitas A, Coelho J, Watanabe M, Lima R . RELATIONSHIP BETWEEN DONOR QUALITY AND RECIPIENT GRAVITY IN LIVER TRANSPLANT. Arq Bras Cir Dig. 2020; 33(1):e1499. PMC: 7357553. DOI: 10.1590/0102-672020190001e1499. View

Parikh N, Singal A . Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2019; 7(5):97-100. PMC: 6490268. DOI: 10.1002/cld.545. View

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

Carrilho F, Kikuchi L, Branco F, Goncalves C, Mattos A . Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo). 2011; 65(12):1285-90. PMC: 3020338. DOI: 10.1590/s1807-59322010001200010. View

10.

Yao F, Ferrell L, Bass N, Watson J, Bacchetti P, Venook A . Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33(6):1394-403. DOI: 10.1053/jhep.2001.24563. View

11.

Northup P, Intagliata N, Shah N, Pelletier S, Berg C, Argo C . Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology. 2014; 61(1):285-91. DOI: 10.1002/hep.27283. View

12.

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

13.

Rodriguez S, Fleck Jr A, Mucenic M, Marroni C, Brandao A . HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS. Arq Gastroenterol. 2020; 57(1):19-23. DOI: 10.1590/S0004-2803.202000000-05. View

14.

Yao F, Bass N, Nikolai B, Davern T, Kerlan R, Wu V . Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002; 8(10):873-83. DOI: 10.1053/jlts.2002.34923. View

15.

Kim B, Kahn J, Terrault N . Liver transplantation as therapy for hepatocellular carcinoma. Liver Int. 2020; 40 Suppl 1:116-121. DOI: 10.1111/liv.14346. View

16.

Sharma P, Balan V, Hernandez J, Harper A, Edwards E, Rodriguez-Luna H . Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 2004; 10(1):36-41. DOI: 10.1002/lt.20012. View

17.

Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M . Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019; 20(6). PMC: 6470669. DOI: 10.3390/ijms20061358. View

18.

Schlansky B, Chen Y, Scott D, Austin D, Naugler W . Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Liver Transpl. 2014; 20(9):1045-56. DOI: 10.1002/lt.23917. View

19.

Yao F, Ferrell L, Bass N, Bacchetti P, Ascher N, Roberts J . Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002; 8(9):765-74. DOI: 10.1053/jlts.2002.34892. View

20.

Wiesner R, Freeman R, Mulligan D . Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004; 127(5 Suppl 1):S261-7. DOI: 10.1053/j.gastro.2004.09.040. View